Our results show that LTx patients heterozygous for rs2476601 are more susceptible for BOS development and indicate a deleterious effect of the autoimmune-related risk factor of PTPN22 in patients on LTx outcome. This evidence concerns the gene PTPN22 and Buschke-Ollendorff syndrome.